Global Conference 2017

Technology has had a dramatically disruptive impact in medical research, perhaps most remarkably in genomics. Nearly two decades after the initial sequencing of the human genome, scientists are unlocking new ways to understand the cellular basis of disease through big data analysis, artificial intelligence and machine learning. This private discussion will examine how far we've come and explore where we may be headed next.

  • Which areas of medical research and technology hold the most promise?
  • What models of collaboration--across bioscience and technology companies, foundations, research institutions and government agencies--will yield the best results?
  • How can we further accelerate medical research through technology?


Jonathan Simons

President and CEO, Prostate Cancer Foundation; Senior Advisor, Milken Institute


Matthew Collier

Senior Advisor to the Secretary for Strategic Partnerships, U.S. Department of Veterans Affairs

Wyatt Decker

Vice President, Mayo Clinic; Chief Executive Officer, Mayo Clinic, Arizona

Bob Hugin

Executive Chairman, Celgene Corporation

Eric Lefkofsky

Co-Founder and CEO, Tempus

Richard Merkin

Founder and CEO, Heritage Group; Board Member, FasterCures

Andrew von Eschenbach

President, Samaritan Health Initiatives Inc.; former Commissioner, U.S. Food and Drug Administration; former Director, National Cancer Institute; Senior Fellow, Milken Institute

Return to Program Detail